IMPORTANT LEGAL NOTICE - The information on this site is subject to adisclaimerand acopyright notice
 
Contact   |   Search  
Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element
Cell factory - Back to the homepage Graphic element Graphical element
Foreword Graphic element Graphical element
Table of contents Graphical element
Index by Index by Area Index by Partners Index by Keywords Graphic element Graphical element
Volume 2 Graphical element

a   |  b   |  c   |  d   |  e   |  f   |  g   |  h   |  i   |  j   |  k   |  l   |  m   |  n   |  o   |  p   |  q   |  r   |  s   |  t   |  u   |  v   |  w   |  x   |  y   |  z  |
Graphical element
 
affinity tags
  QLK3-2001-00448 Development of highly specific enzymes for genome manipulation (EnGeM)
 
algal database
  QLK3-2002-02132 Microalgae as cell factories for chemical and biochemical products (ALGINET)
 
allele frequencies
  QLK3-2002-01969 Protecting the benefits of Bt-toxins from insect resistance development by monitoring and management (ProBenBt)
 
allele screening
  QLK3-2002-01772 Blood grouping and genotyping: Improving patient safety and blood transfusion compatibility (BloodGen)
 
alloimmunisation
  QLK3-2002-01772 Blood grouping and genotyping: Improving patient safety and blood transfusion compatibility (BloodGen)
 
alpha-synuclein
  QLK3-2002-02114 European network to develop new therapeutic strategies for Parkinson's Disease using lentiviral vector technology ((N)EUROPARK)
 
anaplerotic pathways
  QLK3-2002-02038 Demonstration of increased yield and productivity in selected commercial organisms by strategic transformation of key genes from Aspergillus niger (ANTICO)
 
animal experimentation alternatives
  QLK3-2001-00407 Organotypic brain slice cultures as an alternative to in vivo experimentation in the study of brain repair mechanisms (ORCA)
 
animal experimentation reduction
  QLK3-2001-00401 Prevalidation of novel alternative pharma-/toxicological screening based on yeast expression technology (MULTIPLEX)
 
anti-fouling coatings
  QLK3-2002-01938 Phototrophic biofilms and their potential applications: Towards the development of a unifying concept (PHOBIA)
 
antigen transfer
  QLK3-2002-01980 Development of an immunotherapy for breast cancer based on dendritic cells by developing and comparing different types of tumour-specific immunogens (Cancer Immutherapy)
 
antigen-specific immune responses
  QLK3-2001-00422 Targeting heme-oxygenase-1 or downstream processes: A new therapeutic approach for treatment of inflammation (HO-1)
 
anti-infective agents
  QLK3-2001-00305 Deoxyuridine triphosphate nucleotidohydrolase as drug target for the control of protozoal and bacterial infections (dUTPase)
 
anti-inflammatory action
  QLK3-2002-02031 Neuropeptides for lung treatment of rare lung diseases, primary and secondary pulmonary hypertension (Neuropeotide Lung Therapy)
 
anti-inflammatory effectors
  QLK3-2001-00422 Targeting heme-oxygenase-1 or downstream processes: A new therapeutic approach for treatment of inflammation (HO-1)
 
antimicrobials
  QLK3-2002-02056 Gene mining of metagenomes for novel enzymes and therapeutics (Gemini)
 
anti-proliferative action
  QLK3-2002-02031 Neuropeptides for lung treatment of rare lung diseases, primary and secondary pulmonary hypertension (Neuropeotide Lung Therapy)
 
antitumour therapy
  QLK3-2002-02003 European standard operating procedures for electrochemotherapy and electrogenetherapy (ESOPE)
 
anti-viral chemotherapy
  QLK3-2001-00506 Research, selection and mechanism of action of potential therapeutic agents against Flaviviridae (Hepatitis C virus, Dengue virus, West Nile virus) (Flavitherapeutics)
 
antobiotics
  QLK3-2001-00277 Development of novel anti-bacterials and anti-infectives that target programmed bacterial cell death (BAS anti-microbials)
 
aromatic effectors
  QLK3-2002-01923 Biosensors for in situ evaluation of bioavailability of pollutants based on transcriptional regulators la carte (BIOCARTE)
 
arterioprotective therapies
  QLK3-2002-01955 Therapeutic strategies using VEGF substitutes and gene therapies to maintain the integrity of the arterial wall (VEGF Strategies)
 
artherosclerosis
  QLK3-2002-01955 Therapeutic strategies using VEGF substitutes and gene therapies to maintain the integrity of the arterial wall (VEGF Strategies)
 
artificial neural networks
  QLK3-2002-01938 Phototrophic biofilms and their potential applications: Towards the development of a unifying concept (PHOBIA)
  QLK3-2002-01939 Micro-arrays for the detection of the abundance and distribution of pathogenic protozoa, flagellated algae and diatoms (MICROPAD)
 
autoantibodies
  QLK3-2002-02017 Clearance of apoptotic cells: Discovery of autoantigens and therapy for autoimmune diseases (APOCLEAR)
 
autoimmune disease
  QLK3-2002-01936 Predicting outcome and developing new therapeutic strategies for haematological stem cell transplant recipients using in vitro techniques (TRANSEUROPE)
 
avidin-biotin binding
  QLK3-2001-02166 A Fusion Gene for the Treatment of Cancer (Scavidin)
Graphical element
a   |  b   |  c   |  d   |  e   |  f   |  g   |  h   |  i   |  j   |  k   |  l   |  m   |  n   |  o   |  p   |  q   |  r   |  s   |  t   |  u   |  v   |  w   |  x   |  y   |  z  |
Graphical element